E-LIB Suche - Ergebnisse für: Schwartz, A. G.

1

Two of a kind: mass and molar immunoassay-based lipoprotein..:

Szarek, M ; Steg, P G ; Jukema, J W...
European Heart Journal. 44 (2023) Supplement_2 - p. , 2023

Link: https://doi.org/10.1093/..

2

Lipoprotein(a) and the effect of alirocumab on coronary and..:

Steg, P ; Szarek, M ; Valgimigli, M...
European Heart Journal. 43 (2022) Supplement_2 - p. , 2022

Link: https://doi.org/10.1093/..

3

Longer-term safety of alirocumab with 24,610 patient-years ..:

Goodman, S ; Steg, P G ; Szarek, M...
European Heart Journal. 43 (2022) Supplement_2 - p. , 2022

Link: https://doi.org/10.1093/..

4

Effect of inclisiran on haematological and immunological bi..:

Landmesser, U. ; Conde, L. Garcia ; Wright, R.S....
Atherosclerosis. 331 (2021) - p. e37 , 2021

Link: https://doi.org/10.1016/..

5

Reduction in the risk of MACE with apabetalone in patients ..:

Toth, P P ; Schwartz, G G ; Nicholls, S J...
European Heart Journal. 42 (2021) Supplement_1 - p. , 2021

Link: https://doi.org/10.1093/..

6

Efficacy and safety of inclisiran in patients with establis..:

Koenig, W ; Ray, K K ; Kallend, D G...
European Heart Journal. 42 (2021) Supplement_1 - p. , 2021

Link: https://doi.org/10.1093/..

7

Efficacy and safety of inclisiran in patients with polyvasc..:

Koenig, W ; Ray, K K ; Kallend, D G...
European Heart Journal. 42 (2021) Supplement_1 - p. , 2021

Link: https://doi.org/10.1093/..

8

Inter-individual variability in LDL-C reductions with incli..:

Wright, R.S ; Raal, F.J ; Kallend, D...
European Heart Journal. 41 (2020) Supplement_2 - p. , 2020

Link: https://doi.org/10.1093/..

9

Apabetalone, a selective BET protein inhibitor, reduces isc..:

Ray, K.K ; Nicholls, S.J ; Buhr, K.A...
European Heart Journal. 41 (2020) Supplement_2 - p. , 2020

Link: https://doi.org/10.1093/..

10

Low-density lipoprotein cholesterol <50 mg/dL is an appropr..:

Schwartz, G.G ; Szarek, M ; Bhatt, D.L...
European Heart Journal. 41 (2020) Supplement_2 - p. , 2020

Link: https://doi.org/10.1093/..

11

Effect of inclisiran on atherogenic lipoproteins in high-ri..:

Ray, K.K. ; Kallend, D. ; Leiter, L.A....
Atherosclerosis. 315 (2020) - p. e8 , 2020

Link: https://doi.org/10.1016/..

12

Baseline triglycerides and non-HDL-C and apoB goal attainme..:

Ray, K.K ; Kallend, D ; Raal, F.J...
European Heart Journal. 41 (2020) Supplement_2 - p. , 2020

Link: https://doi.org/10.1093/..

13

Effect of alirocumab on incidence of atrial fibrillation af..:

Lopes, R ; Steg, P.G ; Bhatt, D.L...
European Heart Journal. 41 (2020) Supplement_2 - p. , 2020

Link: https://doi.org/10.1093/..

14

P4608BET-inhibition with Apabetalone in Post-ACS Patients w..:

Ray, K K ; Nicholls, S J ; Sweeney, M...
European Heart Journal. 40 (2019) Supplement_1 - p. , 2019

Link: https://doi.org/10.1093/..

15

4114Efficacy of alirocumab treatment after acute coronary s..:

Roe, M T ; Szarek, M ; Li, Q H...
European Heart Journal. 40 (2019) Supplement_1 - p. , 2019

Link: https://doi.org/10.1093/..